Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have earned an average recommendation of “Buy” from the ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hund ...

GreenLight Biosciences, Inc., a Boston-based agtech company with lab, office and greenhouse space in RTP, has closed a Series C funding round, including a $25 million investment from a new investor, ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), ...

The firm will use the proceeds to advance AIR-001 as its lead candidate and file a clinical trial application later this year.

None of the cell and gene therapies that reached the final regulatory submission stage were rejected by the FDA.

The global US Plasma Fractionation Market is projected to reach US$13.80 billion by 2028 from US$10.13 billion in 2023, at a ...

AIR-001 is designed to restore functional alpha-1 antitrypsin (M-AAT) protein production by precisely repairing the SERPINA1 mutation (PiZ) to address the underlying cause of both lung and liver ...

In this week’s edition of InnovationRx, we look at Trump's massive health agency layoffs, Palantir’s trade secret lawsuit, ...

Emmerdale fans have rumbled Joe Tate's return to the village as they think he'll make his way back for Dawn as the pair go on ...

The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.